Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
1. All consecutive patients with Cirrhosis and ascites admitted to ILBS (Institute of Liver
& Biliary Sciences) will be evaluated for the presence of SBP (Spontaneous Bacterial
Peritonitis) by ascitic fluid examination at admission.
2. SBP (Spontaneous Bacterial Peritonitis) will be diagnosed in the presence of absolute
neutrophil count (ANC >250/mm3) with/without positive ascitic fluid culture and Patients
with SBP (Spontaneous Bacterial Peritonitis) included in the study will be randomized to
receive cefepime or imipenem.
3. However, other SBP (Spontaneous Bacterial Peritonitis) patients not included for
randomization will be given empirical therapy with 3rd generation cephalosporin
(ceftriaxone).